Filing Details
- Accession Number:
- 0001181431-14-034515
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-10-20 16:10:50
- Reporting Period:
- 2014-10-16
- Filing Date:
- 2014-10-20
- Accepted Time:
- 2014-10-20 16:10:50
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 879169 | Incyte Corp | INCY | Services-Commercial Physical & Biological Research (8731) | 943136539 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1454983 | S Richard Levy | Experimental Station Route 141 And Henry Clay Rd Wilmington DE 19880 | Evp, Chief Drug Dev&Medical Of | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2014-10-16 | 8,000 | $14.72 | 12,301 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2014-10-16 | 8,000 | $49.03 | 4,301 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2014-10-16 | 8,000 | $0.00 | 8,000 | $14.72 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 44,317 | 2018-01-24 | No | 4 | M | Direct |
Footnotes
- Beginning January 25, 2011, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years.
- This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- Represents weighted average sale price. Actual sales prices ranged from $47.33 - $49.76.
- Reporting person undertakes to provide upon request by Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares.
Billionaire Hedge Funds
